What is the recommended definitive treatment for a large, unresectable lesion?

Definitive Treatment for Large, Unresectable Lesions

For large, unresectable soft tissue sarcomas, definitive high-dose radiotherapy (60-70 Gy) is the primary treatment, with systemic chemotherapy added for high-risk disease or chemosensitive subtypes. 1, 2

Treatment Algorithm

Initial Management Steps

Biopsy first - Always obtain tissue diagnosis before initiating treatment for unresectable disease 1. This is non-negotiable as it guides all subsequent therapy decisions.

Primary Treatment Options (in order of preference):

1. Definitive Radiotherapy

   • Dose: 60-66 Gy for conventional fractionation 2 or 70.2 Gy (RBE) in 26 fractions for proton therapy 3
   • Proton therapy offers superior outcomes for unresectable trunk sarcomas with 3-year local control of 81% and overall survival of 51%, with no grade ≥3 toxicities 3
   • Consider tissue displacement spacers to protect bowel from high-dose radiation volumes 1

2. Combined Radiotherapy + Systemic Therapy

   • Add chemotherapy for:
     • High risk for metastatic disease
     • Chemosensitive subtypes (myxoid round cell sarcoma, synovial sarcoma, uterine leiomyosarcoma, DSRCT) 2
     • Predicted 5-year survival <60% on nomograms 2
   • Most active regimen: AIM (doxorubicin/ifosfamide/mesna) 1

3. Systemic Therapy Alone

   • Reserved for patients with:
     • Stage IV disease
     • Medical contraindications to radiotherapy
     • Rapidly progressive disease requiring immediate systemic control

4. Observation

   • Only appropriate if:
     • Patient is asymptomatic AND
     • Tumor growth is indolent 1

Critical Decision Points

Do NOT use systemic therapy for low-grade tumors 1 - this is a common pitfall where treatment causes more harm than benefit.

Reassess resectability after primary treatment - If the tumor becomes resectable after radiotherapy ± chemotherapy, proceed to surgical resection using the same principles as primary resectable disease 1.

Surveillance Protocol

Follow with physical exam and CT (preferred) or MRI of chest/abdomen/pelvis:

• Every 3-6 months for years 2-3
• Every 6 months for years 4-5
• Annually thereafter 1

Evidence Quality Discussion

The most recent and highest-quality evidence comes from the 2025 UK guidelines 2 and 2022 NCCN guidelines 1, both representing expert consensus from major cancer organizations. The 2026 prospective registry study on proton therapy 3 provides the strongest single-study evidence for definitive radiotherapy outcomes, showing maintained quality of life with excellent local control rates.

Key caveat: The guidelines emphasize that R1/R2 resections followed by adjuvant RT should NOT be routine unless local recurrence would cause unacceptable morbidity 1. This challenges the reflexive "cut it out then radiate" approach.